How Is Life After Severe COVID-19?: Functional Cardiopulmonary Outcome and Quality of Life

Maurizio Bernasconi1, Camelia Voinea1, Luca Sardella1

  • 1Pulmonology Division, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.

CHEST Pulmonary
|August 4, 2026
PubMed

Insights

One year after severe COVID-19, many patients experience persistent cardiopulmonary limitations and significant psychosocial impacts. These long-term effects on physical function and daily life require comprehensive management strategies for COVID-19 survivors.

Area of Science:

  • Pulmonology
  • Critical Care Medicine
  • Rehabilitation Medicine

Background:

  • Long-term outcomes of COVID-19-related Acute Respiratory Distress Syndrome (ARDS) are not well-documented, with limited data beyond patient-reported symptoms.
  • Severe COVID-19 requiring intensive care unit (ICU) management and mechanical ventilation can lead to persistent health issues.

Purpose of the Study:

  • To investigate the 12-month cardiopulmonary function and psychosocial sequelae in patients who experienced severe COVID-19 and required intubation.
  • To assess the functional limitations and health perception one year post-ICU admission for COVID-19.

Main Methods:

  • A longitudinal cohort study of 39 mechanically ventilated COVID-19 patients from the early pandemic phase.
  • Collected data included pulmonary function tests, cardiopulmonary exercise testing, and subjective health perception at 6 and 12 months post-ICU admission.

Main Results:

  • At 12 months, 19.3% had moderate pulmonary function alterations and 35.7% showed reduced effort capacity on exercise testing.
  • Over 70% reported significant health impairment due to respiratory symptoms, impacting daily activities and work resumption (only 41.7% fully resumed work).
  • Health perception scores did not correlate with objective cardiopulmonary or lung function measures.

Conclusions:

  • Patients surviving severe COVID-19 ARDS exhibit persistent objective physical limitations and significant psychosocial sequelae 12 months post-ICU.
  • The observed health impairment is likely multifactorial, involving physical and psychological components, necessitating integrated care approaches.
  • Findings highlight the need for long-term management programs considering the complex and prolonged recovery course for COVID-19 survivors.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: